Nuvilex to Relocate Corporate Headquarters to FDA’s Backyard

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) announced today it is in the final stages of locating its International Corporate Headquarters near the headquarters of the U.S. Food and Drug Administration (FDA).

By locating the Company’s International Corporate offices 4 miles from the U.S. FDA, the Company will have immediate access to the agency’s resources. In addition, the new HQ will be located approximately 10 miles from the National Institutes of Health and the National Cancer Institute, both major sources of grants and research collaboration. This move will be of significant value as Nuvilex pursues clinical development of its pancreatic cancer treatment technology as well as additional biotechnology developments planned for the future.

Dr. Robert F. Ryan, Nuvilex’s President and CEO commented, “We strongly believe this location will have significant benefits for the Company. Most importantly, it will facilitate our interactions with the FDA, an important part of our overall strategic planning, especially given our recent entry into biotechnology and our plans for expansion in this area.”

About Nuvilex, Inc.

Nuvilex, Inc. (OTCQB: NVLX) is an innovative biotechnology and natural products company. Nuvilex’s leading oncology offerings under development include a late stage treatment for advanced pancreatic cancer and early stage breast cancer treatment using the company’s industry-leading live-cell encapsulation technology.

The pancreatic cancer treatment is being readied for additional clinical trials and significant advances are in progress with the live-cell encapsulation technology. Current natural products include flagship Gluten-Free Cinnergen™ and others to enhance a healthy lifestyle. Additional offerings include products designed for cosmetic use, flu treatment, and the use of heavy-metal-free tattoo inks. Future developments are planned for Citroxin™ and Oraphyte™, Nuvilex’s antimicrobial and antinematodal agents.

Safe Harbor Statement

This information may contain forward-looking statements involving risks and uncertainties. Results, events and performances could vary from those contemplated. These risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes including product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making investment decisions. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.



CONTACT:

Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
[email protected]

KEYWORDS:   United States  North America  Arizona

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  FDA  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.